Nuvo Research Inc., of Mississauga, Ontario, reacquired Pennsaid 2 percent (diclofenac sodium) for osteoarthritis of the knee marketing rights to South America, Central America, South Africa and Israel from Paladin Labs Inc., of Montreal, for a noncash consideration. Read More
strong>Clovis Oncology Inc., of Boulder, Colo., said it started dosing in the phase II portion of the phase II/III TIGER-1 (Third-Generation Inhibitor of Mutant EGFR in Lung Cancer) study testing rociletinib, its oral, targeted covalent mutant-selective inhibitor of EGFR for the treatment of non-small-cell lung cancer in patients with initial activating EGFR mutations as well as primary resistance mutations T790M. Read More
Prometic Life Sciences Inc., of Laval, Quebec, reported during the American Society of Nephrology meeting in Philadelphia preclinical data showing that PBI-4050, an oral, antifibrotic drug, attenuated development of diabetic nephropathies in type 2 diabetes through the improvement of glycemic control and the inhibition of renal TGFbeta-mediated fibrotic pathways, in association with disease in macrophage infiltration, oxidative stress and increase in autophagy. Read More
Gilead Sciences Inc., of Foster City, Calif., said it priced senior unsecured notes in an aggregate principal amount of $4 billion in a registered public offering consisting of three tranches: $500 million of 2.35 percent senior notes maturing in February 2020; $1.75 billion of 3.5 percent senior notes maturing in February 2025; and $1.75 billion of 4.5 percent senior notes maturing in February 2045. Read More
The World Health Organization (WHO) warned Thursday that global strides made in eliminating measles have stalled, making it unlikely that the goal of reducing measles-related deaths by 95 percent from 2000 to 2015 will be met. Read More
DUBLIN – Glionova AB, a Swedish start-up exploiting a novel mechanism of action in cancer, raised SEK42 million (US$5.7 million) in a series A round to take forward its lead drug, GLN-1001, which is in development for glioblastoma. Read More
As Russia's efforts to bolster its domestic pharma R&D investment grow, the country is becoming more friendly to clinical trial sponsors, according to an executive at privately held R-Pharm, a Moscow-based drug manufacturer and wholesaler. Read More
LONDON – The compelling clinical data and widespread interest in chimeric antigen receptor T-cell (CAR-T) immunotherapies is infecting regulatory agencies worldwide and they are vying to be first to review one of those products, according to Usman Azam, global head of cell and gene therapies at Novartis AG. Read More
Microbicides become far less effective at preventing HIV infection in the presence of semen, a fact that may account for the discrepancy between their ability to kill HIV in vitro and their underwhelming performance in field trials. Read More
BEIJING – At the recent China Trials 7 event, the discussion was far ranging about how to make China a second home market for foreign drug companies and a better home market for local ones, but it is clear that many challenges need to be resolved in the clinical trial space before that can become a reality. Read More
With its injectable version of a topical stain approved to detect eye damage – the first-ever therapeutic use of rose Bengal – on the runway for phase III trials in melanoma, Provectus Biopharmaceuticals Inc. has offered the FDA a comparator-study protocol, while pursuing earlier-stage work with PV-10 in breast and liver tumors as well. Read More
